BHC

6.30

0.16% -0.010

Handel nachbörslich: 6.19 -0.11 -1.75%

Bausch Health Companies Inc (BHC)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

$6.31

Offen:

$6.35

24-Stunden-Volumen:

2.16M

Relative Volume:

1.13

Marktkapitalisierung:

$2.36B

Einnahmen:

$10.53B

Nettoeinkommen (Verlust:

$-1.23B

KGV:

-1.9409

EPS:

-3.246

Netto-Cashflow:

$949.99M

1W Leistung:

+4.30%

1M Leistung:

+10.72%

6M Leistung:

+8.25%

1J Leistung:

+4.83%

1-Tages-Spanne:

$6.20

$6.385

1-Wochen-Bereich:

$5.732

$6.385

52-Wochen-Spanne:

$4.33

$8.00

Bausch Health Companies Inc Stock (BHC) Company Profile

Firmenname

Bausch Health Companies Inc

Sektor

Healthcare (1052)

Branche

Drug Manufacturers - Specialty & Generic (84)

Telefon

514-744-6792

Adresse

2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC

Mitarbeiter

20,300

Twitter

Nächster Verdiensttermin

2026-10-28

Neueste SEC-Einreichungen

BHC's Discussions on Twitter

Compare BHC vs TAK, TEVA, HLN, ZTS, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BHC Bausch Health Companies Inc	6.30	2.36B	10.53B	-1.23B	949.99M	-3.246
TAK Takeda Pharmaceutical Co Adr	19.67	62.84B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	41.50	48.40B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	10.13	44.55B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	79.38	32.80B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	533.12	22.87B	3.17B	1.29B	1.01B	27.09

Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-12-09	Eingeleitet	Barclays	Equal Weight
2024-08-02	Herabstufung	Piper Sandler	Neutral → Underweight
2024-07-10	Eingeleitet	Raymond James	Mkt Perform
2023-09-20	Hochstufung	Jefferies	Hold → Buy
2023-06-16	Herabstufung	TD Cowen	Outperform → Market Perform
2022-07-29	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2022-07-29	Herabstufung	Truist	Buy → Hold
2022-07-28	Herabstufung	JP Morgan	Overweight → Neutral
2022-06-13	Fortgesetzt	JP Morgan	Overweight
2021-03-24	Herabstufung	BofA Securities	Neutral → Underperform
2021-02-17	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2021-01-22	Herabstufung	Piper Sandler	Overweight → Neutral
2020-09-17	Hochstufung	BofA Securities	Underperform → Neutral
2020-08-24	Bestätigt	H.C. Wainwright	Buy
2020-06-17	Bestätigt	H.C. Wainwright	Buy
2020-04-24	Eingeleitet	Citigroup	Buy
2020-04-02	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2020-01-29	Herabstufung	Wolfe Research	Outperform → Peer Perform
2020-01-22	Hochstufung	Wells Fargo	Underweight → Equal Weight
2019-12-12	Hochstufung	JP Morgan	Neutral → Overweight
2019-12-02	Eingeleitet	Goldman	Neutral
2019-10-25	Eingeleitet	Cowen	Outperform
2019-09-12	Eingeleitet	Guggenheim	Buy
2019-08-15	Hochstufung	TD Securities	Hold → Buy
2019-07-19	Eingeleitet	Wolfe Research	Outperform
2019-06-11	Fortgesetzt	Barclays	Overweight
2019-05-13	Hochstufung	JP Morgan	Underweight → Neutral
2019-03-20	Eingeleitet	SunTrust	Buy
2019-01-02	Hochstufung	Piper Jaffray	Neutral → Overweight
2018-11-05	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2018-09-13	Hochstufung	Piper Jaffray	Underweight → Neutral

Alle ansehen

Bausch Health Companies Inc Aktie (BHC) Neueste Nachrichten

Oct 12, 2026

Bausch + Lomb CEO Saunders departs, Chairman Appio named interim chief - Reuters

Oct 12, 2026

Thomas J. Appio Named Interim CEO of Bausch + Lomb as Brent Saunders Departs - VisionMonday.com

Oct 12, 2026

What Could Bausch Health (TSX:BHC) Reveal in Its Next Results? - Kalkine Media

Oct 12, 2026

Bausch + Lomb CEO Saunders steps down, Chairman Appio appointed interim chief - The Mighty 790 KFGO

Oct 12, 2026

Bausch Health study shows improved cirrhosis care adherence By Investing.com - Investing.com Canada

Oct 12, 2026

Bausch Health study shows modest gains in cirrhosis care adherence - StreetInsider

Oct 12, 2026

Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway - PR Newswire

Oct 12, 2026

Bausch + Lomb Names Thomas J. Appio Interim CEO - www.tokenpost.com

Oct 12, 2026

Bausch + Lomb names Appio interim CEO as Saunders departs - StreetInsider

Oct 12, 2026

Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance - The Globe and Mail

Oct 12, 2026

Oct 10, 2026